You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
Merck
Medtronic
Express Scripts
AstraZeneca

Last Updated: January 23, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Galeterone

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Galeterone?

Galeterone is an investigational drug.

There have been 4 clinical trials for Galeterone. The most recent clinical trial was a Phase 1 trial, which was initiated on June 1st 2015.

The most common disease conditions in clinical trials are Prostatic Neoplasms, Pancreatic Neoplasms, and Adenocarcinoma. The leading clinical trial sponsors are Tokai Pharmaceuticals, University of Maryland, Baltimore, and [disabled in preview].

There are twenty-three US patents protecting this investigational drug and one hundred and fourteen international patents.

Recent Clinical Trials for Galeterone
TitleSponsorPhase
1911GCCC: Galeterone or Galeterone With Gemcitabine for Patients With Metastatic Pancreatic AdenocarcinomaUniversity of Maryland, BaltimorePhase 2
Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled GaleteroneTokai PharmaceuticalsPhase 1
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPCTokai PharmaceuticalsPhase 3

See all Galeterone clinical trials

Clinical Trial Summary for Galeterone

Top disease conditions for Galeterone
Top clinical trial sponsors for Galeterone

See all Galeterone clinical trials

US Patents for Galeterone

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Galeterone   Start Trial Bifunctional AKR1C3 inhibitors/androgen receptor modulators and methods of use thereof The Trustees of the University of Pennsylvania (Philadelphia, PA)   Start Trial
Galeterone   Start Trial C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens, in vitro biological activities, pharmacokinetics and antitumor activity UNIVERSITY OF MARYLAND BALTIMORE (Baltimore, MD)   Start Trial
Galeterone   Start Trial Indomethacin analogs for the treatment of castrate-resistant prostate cancer Vanderbilt University (Nashville, TN) The Trustees of the University of Pennsylvania (Philadelphia, PA)   Start Trial
Galeterone   Start Trial Compositions and methods for treatment of prostate carcinoma PELLFICURE PHARMACEUTICALS, INC. (La Jolla, CA)   Start Trial
Galeterone   Start Trial C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens, in vitro biological activities, pharmacokinetics and antitumor activity University of Maryland (Baltimore, MD)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Galeterone

Drugname Country Document Number Estimated Expiration Related US Patent
Galeterone World Intellectual Property Organization (WIPO) WO2012142208 2031-04-13   Start Trial
Galeterone Austria AT482969 2025-03-02   Start Trial
Galeterone Australia AU2006218711 2025-03-02   Start Trial
Galeterone Brazil BRPI0607523 2025-03-02   Start Trial
Galeterone Canada CA2599953 2025-03-02   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
Merck
Medtronic
Express Scripts
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.